Theravance Biopharma, Inc. (NASDAQ:TBPH) Receives Average Recommendation of "Hold" from Brokerages

Theravance Biopharma, Inc. (NASDAQ:TBPH - Get Free Report) has been given an average rating of "Hold" by the five research firms that are covering the company, Marketbeat.com reports. Three research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. The average 1-year price target among brokerages that have covered the stock in the last year is $13.75.

Separately, HC Wainwright restated a "buy" rating and issued a $15.00 price objective on shares of Theravance Biopharma in a research report on Monday, September 16th.

Insider Buying and Selling at Theravance Biopharma

In other Theravance Biopharma news, SVP Rhonda Farnum sold 4,000 shares of Theravance Biopharma stock in a transaction dated Monday, November 11th. The stock was sold at an average price of $9.00, for a total value of $36,000.00. Following the completion of the sale, the senior vice president now owns 322,743 shares in the company, valued at $2,904,687. The trade was a 1.22 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 6.90% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the stock. Quantbot Technologies LP purchased a new stake in Theravance Biopharma in the third quarter valued at approximately $60,000. China Universal Asset Management Co. Ltd. boosted its holdings in shares of Theravance Biopharma by 64.7% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 9,409 shares of the biopharmaceutical company's stock valued at $76,000 after purchasing an additional 3,696 shares during the last quarter. Ballentine Partners LLC purchased a new stake in shares of Theravance Biopharma during the 3rd quarter valued at $104,000. Hsbc Holdings PLC acquired a new stake in shares of Theravance Biopharma during the 2nd quarter worth $108,000. Finally, XTX Topco Ltd purchased a new position in shares of Theravance Biopharma in the 2nd quarter worth $129,000. 99.10% of the stock is currently owned by hedge funds and other institutional investors.

Theravance Biopharma Stock Performance

TBPH traded up $0.07 during midday trading on Monday, reaching $9.95. 148,250 shares of the company's stock were exchanged, compared to its average volume of 337,999. Theravance Biopharma has a 1-year low of $7.44 and a 1-year high of $11.71. The business's 50-day moving average price is $8.86 and its 200 day moving average price is $8.72.

Theravance Biopharma (NASDAQ:TBPH - Get Free Report) last issued its quarterly earnings data on Tuesday, November 12th. The biopharmaceutical company reported ($0.26) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.10) by ($0.16). The company had revenue of $16.87 million for the quarter, compared to analyst estimates of $16.11 million. Theravance Biopharma had a negative return on equity of 24.79% and a negative net margin of 78.18%. During the same quarter in the prior year, the firm earned ($0.17) earnings per share. As a group, research analysts predict that Theravance Biopharma will post -1.09 EPS for the current fiscal year.

About Theravance Biopharma

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology. In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.